克唑替尼在MET突变或扩增的晚期1型乳头状肾细胞癌中实现持久疾病控制:EORTC 90101 CREATE试验
该II期试验前瞻性评估克唑替尼治疗晚期/转移性1型乳头状肾细胞癌的疗效与安全性。MET+患者中2例达PR,ORR 50%(95%CI 6.8-93.2),缓解持续21.8和37.3个月;MET-患者ORR 6.3%(95%CI 0.2-30.2),1例PR持续>9.9个月。克唑替尼在MET突变或扩增患者中有活性且耐受良好。
要点
- MET+患者ORR 50%,2例PR,DOR分别为21.8和37.3个月。
- MET-患者ORR 6.3%,1例PR持续>9.9个月,提示偶发持久缓解。
- 常见治疗相关不良事件为水肿、疲乏、恶心、腹泻和视物模糊。
核心结论
- 克唑替尼在晚期转移性PRCC1中具有活性且耐受良好,在MET突变或扩增患者中实现客观缓解和持久疾病控制。
- MET阴性和MET状态未知病例中也观察到偶发持久缓解,提示可能存在其他MET改变或替代通路。
研究设计与样本
- II期前瞻性试验(EORTC 90101 CREATE),纳入参考病理确诊的晚期/转移性PRCC1患者。
- 患者接受克唑替尼250 mg口服每日两次,根据肿瘤组织MET基因外显子16-19测序分为MET+和MET-亚队列。
- 主要终点为客观缓解率(ORR);若前12例可评估MET+患者中至少2例达到确认的PR或CR,则最多入组35例。
- 共41例患者知情同意,23例符合条件并接受治疗且可评估。
主要发现
- MET+患者4例中2例达PR、1例SD,ORR 50%(95%CI 6.8-93.2),DOR为21.8和37.3个月,1年PFS率75.0%(95%CI 12.8-96.1),1年OS率75.0%(95%CI 12.8-96.1)。
- MET-患者16例中1例PR持续>9.9个月、11例SD,ORR 6.3%(95%CI 0.2-30.2),1年PFS率27.3%(95%CI 8.5-50.4),1年OS率71.8%(95%CI 41.1-88.4)。
- MET状态未知(MET?)患者3例中1例PR持续>6.9个月、1例SD,ORR 33.3%(95%CI 0.8-90.6),1年PFS率66.7%(95%CI 5.4-94.5),1年OS率100%。
- 事后发现1例MET+患者(PR,DOR 37.3个月)和1例MET-患者(SD)存在MET扩增。
- 常见治疗相关不良事件包括水肿(47.8%)、疲乏(47.8%)、恶心(39.1%)、腹泻(39.1%)和视物模糊(34.8%)。
临床怎么用
- 对于晚期/转移性PRCC1患者,可考虑检测MET基因突变或扩增以筛选克唑替尼潜在获益人群。
- 克唑替尼250 mg每日两次方案在MET+患者中显示较高ORR和持久缓解,但需关注水肿、疲乏等不良事件。
局限性
- 样本量小(共23例可评估),MET+亚组仅4例,置信区间宽。
- MET状态未知患者因技术失败,影响亚组分析。
- MET扩增为事后分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). EXPERIMENTAL DESIGN: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed to MET+/MET- sub-cohorts by the sequencing of exons 16-19 of the MET gene in tumour tissue. The primary end-point was objective response rate (ORR). If at least two of the first 12 eligible and evaluable MET+ patients achieved a confirmed partial response (PR) or complete response (CR) (in accordance with the Response Evaluation Criteria in Solid Tumours, version 1.1), a maximum of 35 patients were enrolled. Secondary end-points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), PFS rate (PFSR), overall survival (OS) and safety. RESULTS: Forty-one patients provided consent, of whom 23 were eligible, treated and evaluable. In four MET+ patients, two achieved PR and one had stable disease (SD) (ORR 50%; 95% confidence interval [CI]: 6.8-93.2), DOR was 21.8 and 37.3 months, 1-year PFSR: 75.0% (95% CI: 12.8-96.1) and 1-year OS: 75.0% (95% CI: 12.8-96.1). Among 16 MET- patients, one achieved a PR lasting more than 9.9 months and 11 had SD (ORR: 6.3%; 95% CI: 0.2-30.2), 1-year PFSR: 27.3% (95% CI: 8.5-50.4) and 1-year OS: 71.8% (95% CI: 41.1-88.4). Among three patients with unknown MET status (MET?) due to technical failure, one achieved PR lasting more than 6.9 months, and one had SD (ORR 33.3%, 95% CI: 0.8-90.6), 1-year PFSR: 66.7% (95% CI: 5.4-94.5) and 1-year OS: 100%. MET amplification was found post hoc in one MET+ patient (PR, DOR: 37.3 months), and one MET- case who had SD. Common treatment-related adverse events were oedema (47.8%), fatigue (47.8%), nausea (39.1%), diarrhoea (39.1%) and blurred vision (34.8%). CONCLUSION: Crizotinib is active and well tolerated in advanced, metastatic PRCC1, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification. Sporadic, durable responses are also seen in MET- and MET? cases, suggesting the presence of other alterations of MET or alternative pathways.
引用
- Schöffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017. PMID: 29149761. doi:10.1016/j.ejca.2017.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。